| Literature DB >> 26926090 |
Giulia Vietti1, Dominique Lison2, Sybille van den Brule3.
Abstract
Several experimental studies have shown that carbon nanotubes (CNT) can induce respiratory effects, including lung fibrosis. The cellular and molecular events through which these effects develop are, however, not clearly elucidated. The purpose of the present review was to analyze the key events involved in the lung fibrotic reaction induced by CNT and to assess their relationships. We thus address current knowledge and gaps with a view to draft an Adverse Outcome Pathway (AOP) concerning the fibrotic potential of CNT.As for many inhaled particles, CNT can indirectly activate fibroblasts through the release of pro-inflammatory (IL-1β) and pro-fibrotic (PDGF and TGF-β) mediators by inflammatory cells (macrophages and epithelial cells) via the induction of oxidative stress, inflammasome or NF-kB. We also highlight here direct effects of CNT on fibroblasts, which appear as a new mode of toxicity relatively specific for CNT. Direct effects of CNT on fibroblasts include the induction of fibroblast proliferation, differentiation and collagen production via ERK 1/2 or Smad signaling. We also point out the physico-chemical properties of CNT important for their toxicity and the relationship between in vitro and in vivo effects. This knowledge provides evidence to draft an AOP for the fibrogenic activity of CNT, which allows developing simple in vitro models contributing to predict the CNT effects in lung fibrosis, and risk assessment tools for regulatory decision.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26926090 PMCID: PMC4772332 DOI: 10.1186/s12989-016-0123-y
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
In vivo lung fibrotic reaction of CNT administered via inhalation
| Inhalation studies | |||||||||||
| Duration | CNT | Dose | Experimental model | Fibrosis | References | ||||||
| Type | Source | Length (μm) | Diameter (nm) | Other | Species | Strain | Methods | ||||
| 1-28d | SWCNT | CNI | 0.1–1 | 0.8–1.2 | 5 mg/m3, 5 h/d, 4d | mouse | C57BL/6 | SSCK, SRS | + | [ | |
| whole body | |||||||||||
| 1y | SWCNT | U | 1–3 | 65 | 5 mg/m3, 5 h/d, 4d | mouse | C57BL/6 | SSCK | + | [ | |
| whole body | |||||||||||
| 2-12d | MWCNT-7 | HCC | / | / | 10 mg/m3, 5 h/d | mouse | C57BL/6 J | MTS | + | [ | |
| whole body | |||||||||||
| 1 to 336d | MWCNT-7 | HCC | 4.3 | / | 5 mg/m3, 5 h/d, 12d | mouse | C57BL/6 J | SRS | + | [ | |
| whole body | |||||||||||
| 17 m | MWCNT-7 | HCC | 1–6 | 40–90 | 5 mg/m3, 5 h/d, 5d/w | mouse | B6C3F1 | H&E | ↑ | [ | |
| whole body | |||||||||||
| 90d | MWCNT-7 | HCC | 5.5–6.2 | 94–98 | 0.2–5 mg/m3, 5 h/d, 4d | rat | F344 | MTS | ++ | [ | |
| whole body | |||||||||||
| 1d-14w | MWCNT | HMS | 0.3–50 | 30–50 | 1–30 mg/m3, 6 h/d | mouse | C57BL/6 | MTS | ++ | [ | |
| nose inh | |||||||||||
| 90d | MWCNT | N | 0.1–10 | 5–15 | 0.1–2.5 mg/m3, | rat | Wistar | H&E | - | [ | |
| 6 h/d, 5d/w, 13w | |||||||||||
| nose inh | |||||||||||
| 90d | MWCNT | N | 0.1–10 | 5–15 | 0.1–2.5 mg/m3 | rat | SH | MTS, LS, GS | - | [ | |
| 6 h/d, 5d/w, 13w | |||||||||||
| nd inh | |||||||||||
nd: not determined. Duration: d: day; w: week; y: year. CNT type: AP: as prepared; COOH: carboxyl; NH2: amino; PD: purified. Source: A: Arkema (France); CNI: Carbon Nanotechnologies Inc. (Houston, TX); CT: Cheap Tubes (Brattlebore, VT); HCC: Hodogaya Chemical Company; HMS: Helix Materials Solution (Richardson, TX); MC: Mitsui & Company (Tokio, Japan); N: Nanocyl (Sambreville, Belgium); NI: NanoIntegris (Skokie, IL); NP: Nanotech Port (Chengdu, China); PIH: produced in-house; SA: Sigma-Aldrich (Lyon, France); SN: Shenzhen Nanoharbor (Shenzhen, China); SNP: Shenzhen Nanotech Port (Shenzhen, China); U: Unidym (Sunnyvale, CA). Other: AD: acetone/sonication dispersed; ALD: atomic layer deposition; BSA: bovine serum albumin; cc-PEI: carboxyl converted PEI; D: dispersed; DPPC: dipalmitoylphosphatidylcholine; F: functionalized; ND: no dispersed; PABS: polyaminobenzene sulfonic acid group; PEG: polyethylene glycol; PEI: polyethyleneimine; PF108-C: cruder stock; PF108-HD: homogeneously dispersed; SD: survanta dispersed; swNH2: sidewall amine. Methods: GS: Gomori staining; H&E: Hematoxylin and eosin stain; hcIll: histopathology collagen type III; LS: Ladewig staining; MTS: Masson's trichrome staining; OH-p: hydroxyl proline, SRS: Sirius red staining; SSCK: Sircol Soluble Collagen; WBc: western blot collagen. Fibrosis: +p < 0.05, ++p < 0.01, +++p < 0.001 as reported in the respective paper; (#) p < 0.05 difference between particle responses as reported in the respective paper; ↑: increase of fibrosis suggested by authors but without statistical evidence
In vivo lung fibrotic reaction of CNT administered via intratracheal injection
| Intratracheal injection studies | |||||||||||
| Duration | CNT | Dose | Experimental model | Fibrosis | References | ||||||
| Type | Source | Length (μm) | Diameter (nm) | Other | Species | Strain | Methods | ||||
| 7-56d | short SWCNT | SN | 0.35–0.7 | 10–20 | 60 μg | Mouse | C57BL/6 J | SSCK, MTS | - | [ | |
| long SWCNT | 5–15 | 10–20 | (3 mg/kg) | + | |||||||
| 14d | SWCNT AMIDE | / | 0.7–1 | 4–6 | F | 10 mg/kg | Mouse | C57BL/6 | MTS, hcI, hcIII, hα-SMA | ++ | [ |
| SWCNT COOH | 0.5–1.5 | 4–5 | F | ++ | |||||||
| SWCNT PABS | 0.5-1 | 1.1 | F | ++ | |||||||
| SWCNT PEG | 0.5–0.6 | 4.5 | F | ++ | |||||||
| 1-180d | MWCNT | SA | 0.5–2 | 20–50 | BSA disp | 1–100 μg | Rat | Sprague–Dawley | SSCK, MTS | - | [ |
| (5–500 μg/kg) | |||||||||||
| 1-91d | MWCNT-7 | MC | 5 | 88 | 40–160 μg | Rat | F344 | MTS | ↑ | [ | |
| (0.2–0.8 mg/kg) | |||||||||||
| 1-30d | short MWCNT | NP | 0.5–2 | 50 | 0.6 mg | Rat | SH | SRS, hcIII | - | [ | |
| long MWCNT | 20–50 | 50 | (3 mg/kg) | ++ | |||||||
| 60d | MWCNT | PIH | 5.9 | 9.7 | 0.5–5 mg | Rat | Sprague–Dawley | OH-p, MTS, ELISAc | +++ | [ | |
| MWCNTg | 0.7 | 11.3 | (2.5–25 mg/kg) | ++ | |||||||
| 60d | MWCNTg | PIH | 0.7 | 20–50 | defects +++ | 2 mg | Rat | Wistar | OH-p, MTS | ++ | [ |
| MWCNTg 600 | defects ++ | (10 mg/kg) | +++ | ||||||||
| MWCNTg 2400 | defects + | +++ | |||||||||
nd: not determined. Duration: d: day; w: week; y: year. CNT type: AP: as prepared; COOH: carboxyl; NH2: amino; PD: purified. Source: A: Arkema (France); CNI: Carbon Nanotechnologies Inc. (Houston, TX); CT: Cheap Tubes (Brattlebore, VT); HCC: Hodogaya Chemical Company; HMS: Helix Materials Solution (Richardson, TX); MC: Mitsui & Company (Tokio, Japan); N: Nanocyl (Sambreville, Belgium); NI: NanoIntegris (Skokie, IL); NP: Nanotech Port (Chengdu, China); PIH: produced in-house; SA: Sigma-Aldrich (Lyon, France); SN: Shenzhen Nanoharbor (Shenzhen, China); SNP: Shenzhen Nanotech Port (Shenzhen, China); U: Unidym (Sunnyvale, CA). Other: AD: acetone/sonication dispersed; ALD: atomic layer deposition; BSA: bovine serum albumin; cc-PEI: carboxyl converted PEI; D: dispersed; DPPC: dipalmitoylphosphatidylcholine; F: functionalized; ND: no dispersed; PABS: polyaminobenzene sulfonic acid group; PEG: polyethylene glycol; PEI: polyethyleneimine; PF108-C: cruder stock; PF108-HD: homogeneously dispersed; SD: survanta dispersed; swNH2: sidewall amine. Methods: GS: Gomori staining; H&E: Hematoxylin and eosin stain; hcIll: histopathology collagen type III; LS: Ladewig staining; MTS: Masson's trichrome staining; OH-p: hydroxyl proline, SRS: Sirius red staining; SSCK: Sircol Soluble Collagen; WBc: western blot collagen. Fibrosis: +p < 0.05, ++p < 0.01, +++p < 0.001 as reported in the respective paper; (#) p < 0.05 difference between particle responses as reported in the respective paper; ↑: increase of fibrosis suggested by authors but without statistical evidence
in vivo lung fibrotic reaction of CNT administered via pharyngeal aspiration
| Pharyngeal aspiration studies | |||||||||||
| Duration | CNT | Dose | Experimental model | Fibrosis | References | ||||||
| Type | Source | Length (μm) | Diameter (nm) | Other | Species | Strain | Methods | ||||
| 2w | SD SWCNT | CNI | 0.1–1 | 0.8–1.2 | survanta acetone disp | 10 μg | mouse | C57BL/6 J | SSCK, WBc | + | [ |
| AD SWCNT | (0.5 mg/kg) | + | |||||||||
| 1-28d | SWCNT | CNI | 0.1–1 | 0.8–1.2 | 5–20 μg | mouse | C57BL/6 | SSCK, SRS | ↑ | [ | |
| (0.25–1 mg/kg) | |||||||||||
| 1-60d | SWCNT | CNI | / | 1–4 | 10–40 μg | mouse | C57BL/6 | SRS, MTS | + | [ | |
| (0.5–2 mg/kg) | |||||||||||
| 28d | SWCNT | CNI | / | 1–4 | 40 μg | mouse | C57BL/6 | SSCK | + | [ | |
| (2 mg/kg) | C57BL/6gp91phox−/− | - | |||||||||
| 28d | SWCNT | CNI | 0.7 | 1–4 | 40 μg | mouse | C57BL/6 | SRS, SSCK | + | [ | |
| (2 mg/kg) | B6.129X1-MPO | + (#) | |||||||||
| 3w | SWCNT | CNI | 0.5–2 | 0.4–1.2 | 40 μg | mouse | C57BL/6 | SSCK, MTS | + | [ | |
| twice a week 3 weeks | |||||||||||
| 7d | SWCNT | CNI | 1–3 | 1–4 | 40–80 μg | mouse | C57BL/6 | SSCK | + | [ | |
| (2–4 mg/kg) | |||||||||||
| 28d | SWCNT | U | 1–3 | 1–4 | 40 μg | mouse | C57BL/6 | SRS, SSCK | + | [ | |
| (2 mg/kg) | |||||||||||
| 1y | SWCNT | U | 1–3 | 65 | 40 μg | mouse | C57BL/6 | SSCK | + | [ | |
| (2 mg/kg) | |||||||||||
| 21d | SWCNT BSA-AP-Hipco | NI | 1000–5000 | 0.7–1.1 | BSA-coated | 2 mg/kg | mouse | C57BL/6 | SSCK, MTS | + | [ |
| SWCNT PF108-Hipco | 500–1500 | 0.7–1.1 | PF-108-coated | - | |||||||
| 14-56d | SWCNT | / | 5–15 | <2 | 80 μg/m | mouse | C57BL/6 | OH-p, MTS | + | [ | |
| (4 mg/kg) | |||||||||||
| 90d | Short SWCNT | CT | 1 | 11 | 40 μg/m | mouse | C57BL/6 J | SSCK, SRS | + | [ | |
| Long SWCNT | 13 | 11 | (2 mg/kg) | + (#) | |||||||
| 21d | MWCNT | CT | 10–30 | 20–30 | 2 mg/kg | mouse | C57BL/6 | SSCK, MTS | + | [ | |
| P47phox−/− C57BL/6 | - | ||||||||||
| 21d | MWCNT AP | CT | 0.57 | F | + | ||||||
| MWCNT NH2 | From AP | 0.45 | F | + | |||||||
| MWCNT sw-NH2 | From AP | 0.58 | F | + | |||||||
| MWCNT PEI | From AP | 0.33 | / | F | 2 mg/kg | mouse | C57BL/6 | SSCK, MTS | + (#) | [ | |
| MWCNT cc-PEI | From AP | - | F | + | |||||||
| MWCNT COOH | From AP | 0.38 | F | - | |||||||
| MWCNT PEG | From AP | 0.27 | - | ||||||||
| 21d | AP MWCNT D | CT | BSA + DPPC | + | |||||||
| AP MWCNT ND | CT | / | - | ||||||||
| PD MWCNT D | From AP | 10–30 | 20–30 | BSA + DPPC | 2 mg/kg | mouse | C57BL/6 | MTS, SSCK | + | [ | |
| PD MWCNT ND | From AP | / | - | ||||||||
| COOH MWCNT D | From AP | BSA + DPPC | + | ||||||||
| COOH MWCNT ND | From AP | / | - | ||||||||
| 21d | AP MWCNT | CT | 1.97 | BSA-dispersed | + | ||||||
| AP MWCNT | CT | 1.16 | PF108-C | - | |||||||
| AP MWCNT | CT | 0.15 | PF108-HD | - | |||||||
| PD MWCNT | From AP | 2.11 | BSA-dispersed | + | |||||||
| PD MWCNT | From AP | 1.52 | 20–30 | PF108-C | 2 mg/kg | mouse | C57BL/6 | SSCK, MTS | - | [ | |
| PD MWCNT | From AP | 0.14 | PF108-HD | - | |||||||
| COOH MWCNT | From AP | 1.96 | BSA-dispersed | + | |||||||
| COOH MWCNT | From AP | 1.8 | PF108-C | - | |||||||
| COOH MWCNT | From AP | 0.15 | PF108-HD | - | |||||||
| 1-14d | MWCNT-7 | MC | 3.9 | 49 | 5–40 μg | mouse | C57BL/6 J | MTS, SRS | +++ | [ | |
| (0.25–2 mg/kg) | |||||||||||
| 1-56d | MWCNT-7 | MC | 3.86 | 49 | 10–80 μg | mouse | C57BL/6 J | SRS | + | [ | |
| (0.5–4 mg/kg) | |||||||||||
| 1-56d | MWCNT-7 | MC | 3.86 | 49 | 10–80 μg/m | mouse | C57BL/6 J | SRS | + | [ | |
| (0.5–4 mg/kg) | |||||||||||
| 1 to 56d | MWCNT-7 | HCC | 4.3 | / | 80 μg/m | mouse | C57BL/6 J | SRS | + | [ | |
| (4 mg/kg) | |||||||||||
| 28d | MWCNT | HMS | 0.5–40 | 10–30 | Uncoated | 4 mg/kg | mouse | C57BL/6 | MTS | +++ (#) | [ |
| ALD-coated | + | ||||||||||
| 60d | MWCNT NM400 | N | 0.7–3 | 5–35 | +++ | ||||||
| MWCNT NM402 | A | 0.7–4 | 6–20 | 12.5–100 μg/m | mouse | C57B6/6 | OH-p, SRS | +++ | [ | ||
| MWCNT NM400c | N | 0.1–0.5 | 18–35 | (0.6–5 mg/kg) | - | ||||||
| MWCNTg 2400 | PIH | 0.7 | 20–50 | - | |||||||
| 60d | MWCNT NM400 | N | 0.7–3 | 5–35 | ++ | ||||||
| MWCNT long | CT | 10–30 | 11–59 | 100 μg/m | mouse | C57BL/6 | OH-p, SRS | ++ | [ | ||
| MWCNT short | CT | 0.5–2 | 10–47 | (5 mg/kg) | - | ||||||
| MWCNT thick | CT | 10–30 | 15–74 | - | |||||||
nd: not determined. Duration: d: day; w: week; y: year. CNT type: AP: as prepared; COOH: carboxyl; NH2: amino; PD: purified. Source: A: Arkema (France); CNI: Carbon Nanotechnologies Inc. (Houston, TX); CT: Cheap Tubes (Brattlebore, VT); HCC: Hodogaya Chemical Company; HMS: Helix Materials Solution (Richardson, TX); MC: Mitsui & Company (Tokio, Japan); N: Nanocyl (Sambreville, Belgium); NI: NanoIntegris (Skokie, IL); NP: Nanotech Port (Chengdu, China); PIH: produced in-house; SA: Sigma-Aldrich (Lyon, France); SN: Shenzhen Nanoharbor (Shenzhen, China); SNP: Shenzhen Nanotech Port (Shenzhen, China); U: Unidym (Sunnyvale, CA). Other: AD: acetone/sonication dispersed; ALD: atomic layer deposition; BSA: bovine serum albumin; cc-PEI: carboxyl converted PEI; D: dispersed; DPPC: dipalmitoylphosphatidylcholine; F: functionalized; ND: no dispersed; PABS: polyaminobenzene sulfonic acid group; PEG: polyethylene glycol; PEI: polyethyleneimine; PF108-C: cruder stock; PF108-HD: homogeneously dispersed; SD: survanta dispersed; swNH2: sidewall amine. Methods: GS: Gomori staining; H&E: Hematoxylin and eosin stain; hcIll: histopathology collagen type III; LS: Ladewig staining; MTS: Masson's trichrome staining; OH-p: hydroxyl proline, SRS: Sirius red staining; SSCK: Sircol Soluble Collagen; WBc: western blot collagen. Fibrosis: +p < 0.05, ++p < 0.01, +++p < 0.001 as reported in the respective paper; (#) p < 0.05 difference between particle responses as reported in the respective paper; ↑: increase of fibrosis suggested by authors but without statistical evidence
Fig. 1Direct effects of CNT on fibroblasts
Fig. 2Indirect effects of CNT on fibroblasts via macrophages
Fig. 3Indirect effects of CNT on fibroblasts via epithelial cells
In vitro CNT activities on fibroblast, macrophage or epithelial cell
| Cell | CNT | Concentrations | Effects | Mechanisms | References | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Name | Type | Source | Length (μm) | Diameter (nm) | Other | ||||
| Fibroblast | CRL1490 | AP MWCNT D | BSA + DPPC | P | ||||||
| AP MWCNT ND | / | / | ||||||||
| PD MWCNT D | CT | 10–30 | 20–30 | BSA + DPPC | 5 μg/ml | P | nd | [ | ||
| PD MWCNT ND | / | / | ||||||||
| COOH MWCNT D | BSA + DPPC | / | ||||||||
| COOH MWCNT ND | / | / | ||||||||
| Fibroblast | MLg, HFL-1, | MWCNT NM400 | N | 0.7–3 | 5–35 | 7.5–30 μg/cm2 | P | |||
| BALB-3 T3, | MWCNT NM402 | A | 0.7–4 | 6–20 | (12–48 μg/ml) | P | nd | [ | ||
| PMF | MWCNT NM400c | N | 0.1–0.5 | 18–35 | / | |||||
| MWCNTg 2400 | PIH | 0.7 | 20–50 | / | ||||||
| Fibroblast | MLg | MWCNT NM400 | N | 0.7–3 | 5–35 | 7.5–15 μg/cm2 | P | KR, End, Erk 1/2 | ||
| MWCNT long | CT | 10–30 | 11–59 | (12–24 μg/ml) | P | Erk 1/2 | [ | |||
| MWCNT short | CT | 0.5–2 | 10–47 | / | ||||||
| MWCNT thick | CT | 10–30 | 15–74 | / | ||||||
| Fibroblast | NIH-3 T3 | MWCNT | NP | 20–50 | 50 | 15–60 μg/ml | P, C, D | Smad | [ | |
| Fibroblast | CRL1490 | SWCNT | CNI | 0.02–0.24 μg/cm2 | P, C, MMP-9 | nd | [ | |||
| (0.03–0.4 μg/ml) | ||||||||||
| Fibroblast | CRL1490 | SD SWCNT | CNI | 0.1–1 | 0.8–1.2 | SD | 0.02 μg/cm2 | C | nd | [ |
| AD SWCNT | AD | (0.03 μg/ml) | C | |||||||
| Fibroblast | CRL1490 | SWCNT | CNI | 0.1–1 | 0.8–1.2 | 5–25 μg/ml | P, C, TGF-β, VEGF | ROS, p38 | [ | |
| Fibroblast | NHLF | Short SWCNT | CT | 1 | 11 | 0.02–0.2 μg/cm2 | C, TGF-β | ROS | [ | |
| Long SWCNT | 13 | 11 | (0.03–0.4 μg/ml) | C, TGF-β | ||||||
| Fibroblast | WI38-VA13 | MWCNT | SA | 2.5–20 | 6–13 | 1–20 μg/ml | cyt, TGF-β, PDGF | ROS | [ | |
| Fibroblast | L929 | MWCNT | SA | 5.5 | 10–300 μg/ml | cyt | ROS | [ | ||
| Macrophage | THP-1 | SWCNT | NI | 1–5 | 0.8–1.2 | 50 μg/ml | IL-1β | IFM, ROS, End | [ | |
| MWCNT | CT | 10–30 | 20–30 | IL-1β | ||||||
| Macrophage | THP-1 | SWCNT BSA-AP-Hipco | NI | 1000–5000 | 0.7–1.1 | BSA coated | 50–100 μg/ml | IL-1β | IFM | [ |
| SWCNT BSA-PD-Hipco | 500–1500 | 0.7–1.1 | BSA coated | IL-1β | IFM | |||||
| SWCNT PF108-Hipco | 500–1500 | 0.7-1.1 | PF108 coated | / | ||||||
| SWCNT BSA-AP-Arc | 100–1000 | 1.2–2 | BSA coated | IL-1β | nd | |||||
| SWCNT BSA-PD-Arc | 100–1000 | 1.2–2 | BSA coated | IL-1β | nd | |||||
| SWCNT PF108-Arc | 100–1000 | 1.2–2 | PF108 coated | / | ||||||
| SWCNT BSA-PD-SG65 | 450–2000 | 0.7–1 | BSA coated | IL-1β | nd | |||||
| SWCNT PF108-SG65 | 450-2000 | 0.7–1 | PF108 coated | / | ||||||
| Macrophage | THP-1 | MWCNT | BNR | 67 | 2–10 μg/ml | IL-1β | IFM, ROCK, End | [ | ||
| Macrophage | THP-1 | AP MWCNT D | CT | BSA + DPPC | 10–100 μg/ml | IL-1β | nd | |||
| AP MWCNT ND | CT | / | ||||||||
| PD MWCNT D | From AP | 10–30 | 20–30 | BSA + DPPC | [ | |||||
| PD MWCNT ND | From AP | / | ||||||||
| COOH MWCNT D | From AP | BSA + DPPC | ||||||||
| COOH MWCNT ND | From AP | / | ||||||||
| Macrophage | PM, PBMC | short MWCNT | BMS | 1–10 | 5–20 | / | ||||
| long tangled MWCNT | CT | 10–50 | 8–15 | 10–100 μg/ml | / | [ | ||||
| long needle-like MWCNT | MC | 13 | >50 | IL-1β, IL-α | IFM, ROS, Src, Syc, | |||||
| (Mitsui MWCNT-7) | P2X7 R | |||||||||
| Macrophage | PAM | raw MWCNT | / | IL-1β, IL-18 | IFM | |||||
| THP-1 | pure MWCNT | PD | IL-1β, IL-18 | IFM | ||||||
| raw MWCNT COOH | NAM | COOH F | 25–100 μg/ml | / | [ | |||||
| pure MWCNT COOH | COOH F - PD | / | ||||||||
| Macrophage | PHM | DWCNT | PIH | 0.1–100 | 1.2–3.2 | 25 μg/ml | IL-1β, IL-18 | IFM, End, K efflux | [ | |
| Macrophage | RAW 264.7 | MWCNT | SA | 2.5–20 | 6–13 | 2–20 μg/ml | IL-1β, TNF-α, IL-6, IL-10, MCP-1 | NF-kB | [ | |
| Macrophage | THP-1, PBMC | MWCNT | HMS | 0.5–40 | 10–30 | Uncoated | 10–100 μg/ml | IL-1β, TNF-α, | nd | [ |
| ALD-coated | IL-6, OPN | |||||||||
| IL-1β | ||||||||||
| Macrophage | PAM | Short MWCNT | Nth | 1.1 | 30 | 10 μg/ml | / | [ | ||
| Long MWCNT | 20 | 28 | IL-6, IL-8 | ROS | ||||||
| Macrophage | THP-1 | MWCNT AP | CT | 0.57 | F | IL-1β, TGF-β, PDGF | ||||
| MWCNT NH2 | From AP | 0.45 | F | IL-1β, TGF-β, PDGF | ||||||
| MWCNT sw-NH2 | From AP | 0.58 | F | IL-1β, TGF-β, PDGF | ||||||
| MWCNT PEI | From AP | 0.33 | F | 60 μg/ml | IL-1β, TGF-β, PDGF | for IL-1β: IFM, End | [ | |||
| MWCNT PEG | From AP | 0.27 | F | IL-1β, TGF-β | ||||||
| MWCNT cc-PEI | From AP | 0.38 | F | / | ||||||
| MWCNT COOH | From AP | / | ||||||||
| Macrophage | RAW 264.7 | SWCNT | CNI | 1–4 | 100 μg/ml | TGF-β | nd | [ | ||
| Macrophage | RAW 264.7 | Short MWCNT | NP | 0.5–2 | 50 | 15 μg/ml | / | [ | ||
| Long MWCNT | 20–50 | 50 | TGF-β, TNF-α | nd | ||||||
| Macrophage | NR8383 | MWCNT | HMS | 0.3–50 | 10–30 | 10 μg/cm2 | PDGF | nd | [ | |
| (16 μg/ml) | ||||||||||
| Epithelial cell | A549 | Short MWCNT | SN | 0.35–0.7 | 10–20 | 1–16 μg/cm2 | / | [ | ||
| Long MWCNT | 5–15 | 10–20 | (1.6–25.6 μg/ml) | EMT | TGF-β/Smad | |||||
| Epithelial cell | RLE-6TN | MWCNT | NP | 20–50 | 50 | 30 μg/ml | EMT | TGF-β/Smad | [ | |
| Epithelial cell | HBE | MWCNT | HMS | 0.5–40 | 10–30 | 1.5–24 μg/ml | IL-1β, IL-18 | IFM, ROS | [ | |
| IL-8 | ||||||||||
| Epithelial cell | BEAS-2B | MWCNT | BNR | 67 | 1–10 μg/ml | IL-6, IL-8, MIF | NF-kB, p38, | [ | ||
| ERK 1/2, HSP27 | ||||||||||
| Epithelial cell | TT1, ATII | MWCNT 0.6 μm | Nth | 1.1 | 30 | IL-6, IL-8, MCP-1 | ||||
| MWCNT 3 μm | 4.3 | 33 | 1–50 μg/ml | IL-8, MCP-1 | JNK, p38, ERK 1/2 | [ | ||||
| MWCNT 20 μm | 20 | 28 | MCP-1 | |||||||
| Epithelial cell | BEAS-2B | SWCNT BSA-AP-Hipco | NI | 1000–5000 | 0.7–1.1 | BSA coated | TGF-β | |||
| SWCNT BSA-PD-Hipco | 500–1500 | 0.7–1.1 | BSA coated | TGF-β | ||||||
| SWCNT PF108-Hipco | 500–1500 | 0.7–1.1 | PF108 coated | / | ||||||
| SWCNT BSA-AP-Arc | 100–1000 | 1.2–2 | BSA coated | 100 μg/ml | TGF-β | nd | [ | |||
| SWCNT BSA-PD-Arc | 100–1000 | 1.2–2 | BSA coated | TGF-β | ||||||
| SWCNT PF108-Arc | 100–1000 | 1.2–2 | PF108 coated | TGF-β | ||||||
| SWCNT BSA-PD-SG65 | 450–2000 | 0.7–1 | BSA coated | TGF-β | ||||||
| SWCNT PF108-SG65 | 450–2000 | 0.7–1 | PF108 coated | / | ||||||
| Epithelial cell | BEAS-2B | AP MWCNT D | CT | 10–30 | 20–30 | BSA + DPPC | 10–100 μg/ml | TGF-β | [ | |
| AP MWCNT ND | CT | / | / | |||||||
| PD MWCNT D | From AP | BSA + DPPC | TGF-β | |||||||
| PD MWCNT ND | From AP | / | / | nd | ||||||
| COOH MWCNT D | From AP | BSA + DPPC | Few TGF-β | |||||||
| COOH MWCNT ND | From AP | / | Few TGF-β | |||||||
| Epithelial cell | BEAS-2B | MWCNT | SA | 2.5–20 | 6–13 | 2–200 μg/ml | TGF-β, PDGF | ROS | [ | |
nd: not determined. Cell name: A549: human lung adenocarcinoma alveolar epithelial cell line; ATII: primary human alveolar type-II epithelial cells; BALB-3 T3: mouse embryonic fibroblast cell line; BEAS-2B: human bronchial epithelial cell line; CRL1490: human lung fibroblast cell line; HBE: primary human bronchial epithelial cells; HFL-1: human lung fibroblast cell line; L929: mouse fibroblast cell line; MLg: mouse lung fibroblast cell line; NHLF: normal human lung fibroblast cell line; NIH-3 T3: mouse embryonic fibroblast cell line; NR8383: rat alveolar macrophage cell line; PAM: primary alveolar macrophages; PBMC: peripherial blood mononuclear cells; PHM: primary human monocytes; PMF: primary mouse fibroblasts; RAW 264.7: mouse leukemic monocyte macrophage cell line; RLE-6TN: rat alveolar type II epithelial cell line; THP-1: human leukemia monocytic cell line; TT1: transformed human alveolar type-I-like epithelial cells; WI38-VA13: human normal lung fibroblast cell line immortalized with SV40. CNT type: AP: as prepared; COOH: carboxyl; NH2: amino; PD: purified. Source: A: Arkema (France); BMS: Bayer Material Science (Leverkusen, Germany); BNR: Bussan Nanotech Research (Ibaraki, Japan); CNI: Carbon Nanotechnologies Inc. (Houston, TX); CT: Cheap Tubes (Brattlebore, VT); HMS : Helix Materials Solution (Richardson, TX); MC: Mitsui & Company (Tokio, Japan); N: Nanocyl (Sambreville, Belgium); NAM: Nanostructured & Amorphous Materials Inc. (Houston, TX); NI: NanoIntegris (Skokie, IL); NP: Nanotech Port (Chengdu, China); Nth: Nanothinx (Rio Patras, Greece); PIH: produced in house; SA: Sigma-Aldrich (Lyon, France); SN: Shenzhen Nanoharbor (Shenzhen, China). Other: AD: acetone/sonication dispersed; BSA: bovine serum albumin; cc-PEI: carboxyl converted PEI; D: dispersed; DPPC: dipalmitoylphosphatidylcholine; F: functionalized; ND: no dispersed; PEG: polyethylene glycol; PEI: polyethyleneimine; PF108: Pluronic F108; SD: survanta dispersed; swNH2: sidewall amine. Effects: C: collagen; cyt: cytotoxic; D: differentiation of fibroblasts into myofibroblasts; EMT: epithelial mesenchymal transition; IL: interleukin; MCP: monocyte chemoattractant protein; MIF: migration inhibitory factor; MMP-9: matrix metallopeptidase 9; OPN: osteopontin; P: proliferation; PDGF: platelet derived growth factor; TGF: transforming growth factor; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor. Mechanisms: End: endocytosis; ERK 1/2: extracellular signal-regulated kinase; HSP27: heat shock protein 27; IFM: inflammasome; JNK: c-Jun N-terminal kinase; K: potassium; KR: kinase receptor; NF-kB: nuclear factor-kappa B; ROCK: Rho-kinases; ROS: reactive oxygen species
Fig. 4AOP for CNT and lung fibrosis. Legend: Cp: collagen production; D: differentiation; P: proliferation; T: transition in fibroblasts